The Optimization of Mycoplasm Pneumonia Antibiotic Therapy

Launched by CAPITAL MEDICAL UNIVERSITY · Dec 13, 2010

Keywords

ClinConnect Summary

Mycoplasma pneumoniae was one of important atypical pathogens of community acquired pneumonia. As lack of cell wall, β-lactam medicines were invalid, however, macrolides, tetracyclines and quinolones were effective. But from 2001, many countries reported macrolide- resistant Mycoplasma pneumoniae. Typically, erythromycin was first-line antibiotic medicine. With the resistance increasing, Mycoplasm pneumonia treatment will become more and more difficult. Thus, optimization of Mycoplasm pneumonia antibiotic therapy is very important.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Confirmed community acquired pneumonia
• • 2. 60ys≥age≥18 ys
• • 3. Respiratory symptom (cough accompanied by little or no sputum)
• • 4. New infiltration showed by chest radiology(x-ray or CT)
• • 5. Lung signs was not obvious
• • 6. White blood cell\<10,000/mm3
• • 7. Without underlying diseases or mild
• Exclusion Criteria:
• • 1. Age\<18ys or \>60ys
• • 2. Pregnancy or breast-feeding
• • 3. Over one week after the onset of symptoms
• • 4. HIV infection
• • 5. Recent 90-day hospitalized history(length of stay greater than 2 days)
• • 6. Live in nursing homes or rehabilitation hospitals
• • 7. Taken macrolides or quinolones medicines before enrollment